answer text |
<p>The UK Government is a global leader in Research and Development for TB, and one
of the largest funders of TB research worldwide. Increasing access to medicines and
diagnostics in low income countries is a priority for DFID especially for diseases
like TB</p><p> </p><p>DFID is a leading supporter of Product Development Partnerships
(PDPs), bringing together the strengths of academia and the pharmaceutical industry,
in public-private partnerships to develop new therapies and diagnostics for diseases
of poverty. With these partnerships new products can to be developed for public health
needs, de-linking the cost of research and development from the cost of the final
product.</p><p><br> As part of this effort we are investing £37.5m in the TB Alliance
for the development of new drug regimens, particularly where current treatments are
failing due to antimicrobial resistance. This includes an additional £7.5m, announced
by the Secretary of State for International Development at the UNGA 2018 High Level
Meeting on TB.</p><p> </p><p>The UK Government also supports applied health research
relevant to TB service delivery, through a number of partnerships with other UK and
global funders.</p>
|
|